Marine Macrolides to Tackle Antimicrobial Resistance of

Overview

Journal Mar Drugs

Publisher MDPI

Specialties Biology
Pharmacology

Date 2022 Nov 10

PMID 36355013

Authors

Sukamto S Mamada

Firzan Nainu

Ayu Masyita

Andri Frediansyah

Rifka Nurul Utami

Mirnawati Salampe

Talha Bin Emran

Clara Mariana Goncalves Lima

Hitesh Chopra

Jesus Simal-Gandara

Affiliations

Soon will be listed here.

Abstract

Tuberculosis has become a major health problem globally. This is worsened by the emergence of resistant strains of showing ability to evade the effectiveness of the current antimycobacterial therapies. Therefore, the efforts carried out to explore new entities from many sources, including marine, are critical. This review summarizes several marine-derived macrolides that show promising activity against . We also provide information regarding the biosynthetic processes of marine macrolides, including the challenges that are usually experienced in this process. As most of the studies reporting the antimycobacterial activities of the listed marine macrolides are based on in vitro studies, the future direction should consider expanding the trials to in vivo and clinical trials. In addition, in silico studies should also be explored for a quick screening on marine macrolides with potent activities against mycobacterial infection. To sum up, macrolides derived from marine organisms might become therapeutical options for tackling antimycobacterial resistance of .

Citing Articles

In silico study of bioactive compounds derived from Indonesian marine invertebrates as a novel antituberculosis agent.

Masyita A, Septiana E, Bayu A, Bustanussalam B, Panggabean J, Firdayani F Turk J Med Sci. 2024; 54(6):1399-1408.

PMID: 39734349 PMC: 11673630. DOI: 10.55730/1300-0144.5923.

Lack of correlation between surface water area and infection with and the non-tuberculous mycobacteria (NTMs) in patients with cystic fibrosis (CF).

Moore J, Millar B Infect Med (Beijing). 2024; 3(3):100125.

PMID: 39314805 PMC: 11417682. DOI: 10.1016/j.imj.2024.100125.

Advances, opportunities, and challenges in methods for interrogating the structure activity relationships of natural products.

Ancajas C, Oyedele A, Butt C, Walker A Nat Prod Rep. 2024; 41(10):1543-1578.

PMID: 38912779 PMC: 11484176. DOI: 10.1039/d4np00009a.

Marine-Derived Cytosine Arabinoside (Ara-C) Inhibits Biofilm Formation by Inhibiting PEL Operon Proteins (Pel A and Pel B) of Pseudomonas aeruginosa: An In Silico Approach.

Datta S, Singh V, Nag S, Roy D Mol Biotechnol. 2024; .

PMID: 38739212 DOI: 10.1007/s12033-024-01169-8.

References

Miller B, Fratti R, Poschet J, Timmins G, Master S, Burgos M . Mycobacteria inhibit nitric oxide synthase recruitment to phagosomes during macrophage infection. Infect Immun. 2004; 72(5):2872-8. PMC: 387846. DOI: 10.1128/IAI.72.5.2872-2878.2004. View

Mitchison D . The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985; 66(3):219-25. DOI: 10.1016/0041-3879(85)90040-6. View

Hashimoto T, Hashimoto J, Kozone I, Amagai K, Kawahara T, Takahashi S . Biosynthesis of Quinolidomicin, the Largest Known Macrolide of Terrestrial Origin: Identification and Heterologous Expression of a Biosynthetic Gene Cluster over 200 kb. Org Lett. 2018; 20(24):7996-7999. DOI: 10.1021/acs.orglett.8b03570. View

Takiff H, Salazar L, Guerrero C, Philipp W, Huang W, Kreiswirth B . Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother. 1994; 38(4):773-80. PMC: 284541. DOI: 10.1128/AAC.38.4.773. View

Zhang L, Awakawa T, Abe I . Understanding and Manipulating Assembly Line Biosynthesis by Heterologous Expression in Streptomyces. Methods Mol Biol. 2022; 2489:223-238. DOI: 10.1007/978-1-0716-2273-5_12. View

Gandhi N, Moll A, Sturm A, Pawinski R, Govender T, Lalloo U . Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547):1575-80. DOI: 10.1016/S0140-6736(06)69573-1. View

van der Paardt A, Wilffert B, Akkerman O, de Lange W, van Soolingen D, Sinha B . Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. Eur Respir J. 2015; 46(2):444-55. DOI: 10.1183/09031936.00147014. View

Terwilliger D, Trauner D . Selective Synthesis of Divergolide I. J Am Chem Soc. 2018; 140(8):2748-2751. DOI: 10.1021/jacs.7b13092. View

Whicher J, Dutta S, Hansen D, Hale W, Chemler J, Dosey A . Structural rearrangements of a polyketide synthase module during its catalytic cycle. Nature. 2014; 510(7506):560-4. PMC: 4074775. DOI: 10.1038/nature13409. View

10.

Poulsen S, Karlsson M, Johansson L, Vester B . The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol Microbiol. 2001; 41(5):1091-9. DOI: 10.1046/j.1365-2958.2001.02595.x. View

11.

Wilkinson B, Micklefield J . Mining and engineering natural-product biosynthetic pathways. Nat Chem Biol. 2007; 3(7):379-86. DOI: 10.1038/nchembio.2007.7. View

12.

Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L . High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother. 2009; 53(12):5064-8. PMC: 2786337. DOI: 10.1128/AAC.00851-09. View

13.

Gillespie S . Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother. 2002; 46(2):267-74. PMC: 127054. DOI: 10.1128/AAC.46.2.267-274.2002. View

14.

Zhu Z, Krasnykh O, Pan D, Petukhova V, Yu G, Liu Y . Structure-activity relationships of macrolides against Mycobacterium tuberculosis. Tuberculosis (Edinb). 2008; 88 Suppl 1:S49-63. DOI: 10.1016/S1472-9792(08)70036-2. View

15.

Ding L, Maier A, Fiebig H, Gorls H, Lin W, Peschel G . Divergolides A-D from a mangrove endophyte reveal an unparalleled plasticity in ansa-macrolide biosynthesis. Angew Chem Int Ed Engl. 2011; 50(7):1630-4. DOI: 10.1002/anie.201006165. View

16.

Banerjee A, DUBNAU E, Quemard A, Balasubramanian V, Um K, Wilson T . inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994; 263(5144):227-30. DOI: 10.1126/science.8284673. View

17.

Huitric E, Verhasselt P, Andries K, Hoffner S . In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007; 51(11):4202-4. PMC: 2151410. DOI: 10.1128/AAC.00181-07. View

18.

Mabe S, Eller J, Champney W . Structure-activity relationships for three macrolide antibiotics in Haemophilus influenzae. Curr Microbiol. 2004; 49(4):248-54. DOI: 10.1007/s00284-004-4312-9. View

19.

Fischbach M, Walsh C . Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms. Chem Rev. 2006; 106(8):3468-96. DOI: 10.1021/cr0503097. View

20.

Dutta S, Whicher J, Hansen D, Hale W, Chemler J, Congdon G . Structure of a modular polyketide synthase. Nature. 2014; 510(7506):512-7. PMC: 4278352. DOI: 10.1038/nature13423. View